EMA Authorised: Rezurock (belumosudil mesilate) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA authorised Rezurock (belumosudil mesilate) for graft-versus-host disease with conditional approval; Orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• REZUROCK (belumosudil)

Snippet

Status: Authorised. Therapeutic area: Graft vs Host Disease. MAH: Sanofi Winthrop Industrie. Decision date: 24/08/2026. Conditional approval. Orphan medicine